A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma
Titel:
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma
Auteur:
Morschhauser, F. Recher, C. Milpied, N. Gressin, R. Salles, G. Brice, P. Vey, N. Haioun, C. Colombat, P. Rossi, J.F. Deconinck, E. Lazreg, F. Bergougnoux, L. Delsol, G. Attal, M.